Boehringer Ingelheim announced the study outline for the pivotal Phase III clinical trials designed to evaluate BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus (HCV), the most challenging genotype to treat.

GlaxoSmithKline (NYSE:GSK) published a list of payments made during 2010 for clinical research studies led by U.S. healthcare professionals.

Pfizer Inc. released a report detailing the company's financial interactions with health care professionals and researchers in 2010.

Nycomed announced plans for an international phase III/IV study investigating the effect of Daxas® versus placebo on exacerbation rates in COPD patients who are concomitantly treated with fixed combination long-acting-ß2-agonists (LABA) and inhaled corticosteroids (ICS),

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the registration statement relating to the Contingent Value Rights (CVRs) offered to Genzyme shareholders as part of sanofi-aventis' agreement to acquire Genzyme has been declared effective by the U.S. Securities and Exchange Commission.

H. Lundbeck A/S (Lundbeck) strengthens its pipeline of pharmaceuticals in clinical development by initiating clinical phase I studies with Lu AF11167 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans.

Merck KGaA announced that in order to provide assistance to the Japanese people following the earthquake and tsunami that devastated parts of their country, the company will donate a total of 100 million YEN (approximately EUR 875,000).